Spago Nanomedical Q4: Progressing with Tumorad and Pegfosimer Manganese (SpagoPix) - Redeye

Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and Pegfosimer Manganese (SpagoPix) has progressed to a stage where Spago Nanomedical can engage with potential partners. The OPEX base is contained at SEK 12m in Q4.

Länk till analysen i sin helhet: https://www.redeye.se/research/975309/spago-nanomedical-q4-progressing-with-tumorad-and-pegfosimer-manganese-spagopix?utm_source=finwire&utm_medium=RSS